Abstracts

Rationale: We evaluate the efficacy and tolerability of perampanel which is an AMPA receptor antagonist recently approved as an add-on therapy in children, adolescent and adult with intractable epilepsy. Methods: This single-center study retrospectively evaluate the efficacy, tolerability and adverse effect of perampanel in children, adolescent and adult with intractable epilepsy. Results: Adequate data were available on 58 patients taking of perampanel. Thirty-eight patients were male. Seven patients were children, thirty-nine patients adolescents and twelve patients adult. The mean age were 16.9 years (range 3-39 years). Effectiveness rate of perampanel was 72.4% overall (In each group ; children 42.9%, adolescent 71.8%, adult 91.7%). Seizure free was 3.4% overall in only adolescent group. Over 50% seizure reduction rate was 19.0% overall (children 9.0%, adolescent 45.5%, adult 45.5%), less 50% seizure reduction rate was 50.0% overall (children 6.9%, adolescent 72.4%, adult 20.7%). Adverse effect of perampanel was 58.6% overall (In each group ; children 71.4%, adolescent 56.4%, adult 58.3%). Most common adverse effects were sleepiness/fatigue (55.9%), fall down (29.4%), seizure aggravation (23.5%), mood disorder/violence (23.5%), rash (2.9%). Discontinuation of perampanel was 29.3% overall (In each group ; children 57.1%, adolescent 28.2%, adult 16.7%). Most common reasons of drug discontinuation were drug adverse effects such as sleepiness/fatigue (47.1%), seizure aggravation (41.2%), fall down (23.5%), mood disorder/violence (17.6%), rash (5.9%). Mean number of AEDs used in the past was 4.3 ; mean number of concomitant AEDs were 5. Conclusions: Our study found that perampanel is safe, well-tolerated, and effective treatment of children, adolescent and adult with intractable epilepsy. Funding: No potential conflict of interest relevant to this article was reported.